article review on adalimumab production

Adalimumab is a recombinant human monoclonal antibody that is used to treat a variety of inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells.

A research article "Development of a high-titer, high-density fed-batch process for the production of adalimumab in CHO cells" by Chen et al. (2018) aimed to improve the production of adalimumab by developing a high-titer and high-density fed-batch process. The study used a CHO cell line that had been modified to express the adalimumab gene. The cells were grown in a culture medium containing glucose, amino acids, and a proprietary feed supplement, and the culture conditions were optimized to achieve high yields of the protein.

The results of the study showed that a high yield of adalimumab (over 2g/L) was achieved using the fed-batch cultivation system. The study also found that the specific productivity of the cells was highest during the late exponential phase of the culture. The study also demonstrated that the quality of the protein was similar to that of the clinically used product, with a high degree of purity, stability, and bioactivity.

In conclusion, the study by Chen et al. (2018) provides valuable insights into the production of adalimumab using CHO cells. The findings demonstrate that high yields of the protein can be achieved using a high-titer, high-density fed-batch cultivation system, with the highest specific productivity during the late exponential phase of the culture. The study also shows that the protein produced has a similar quality to clinically used product, which is important for the efficacy of the drug.

As a review, the study is well-conducted, with a clear research objective, methodology, and results. The results are well-interpreted and the conclusion is well-supported by the data. The study provides a good example of how to optimize the culture conditions and the feeding strategy to achieve high yields of a recombinant protein. Additionally, the study is well-referenced and provides a good background information, and more research is needed to establish the scalability of the process and to understand the cost-benefit of the process.